ArmaGen Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:ArmaGen Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10888
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:23
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ArmaGen Inc (ArmaGen), formerly ArmaGen Technologies Inc is a clinical stage biotechnology company that develops novel therapies for the treatment of neurological disorders. The company’s pipeline products include AGT-181, AGT-182, AGT-183, AGT-184, AGT-187, AGT-115, AGT-190, AGT-110 and AGT-160. Its products are used for the treatment of neurological symptoms of lysosomal storage diseases. ArmaGen’s products are also used to treat neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease. The company’s technology platform solution targets recombinant proteins, and therapeutic monoclonal antibodies to the brain. ArmaGen is headquartered in Calabasas, California, the US.

ArmaGen Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
ArmaGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ArmaGen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ArmaGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ArmaGen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
ArmaGen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
ArmaGen Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
ArmaGen Technologies Raises US$17 Million In Series A Financing 10
Partnerships 12
ArmaGen Enters into Research Agreement with Rett Syndrome Research Trust 12
Licensing Agreements 13
Shire Enters into Licensing Agreement with ArmaGen for AGT-182 13
ArmaGen Inc – Key Competitors 14
ArmaGen Inc – Key Employees 15
ArmaGen Inc – Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Corporate Communications 17
Jan 19, 2017: ArmaGen Appoints Mathias Schmidt, Ph.D., as Chief Executive Officer 17
Product Approvals 18
Nov 30, 2017: ArmaGen’s AGT-181 Granted Fast Track Designation for the Treatment of Hurler Syndrome (MPS I) 18
Clinical Trials 19
Feb 08, 2018: ArmaGen’s AGT-181 Demonstrates Neurocognitive Benefit in Children with Severe MPS I 19
Feb 16, 2017: ArmaGen Reports Preliminary Evidence of Cognitive Improvement in Children with Hurler Syndrome (MPS I) Treated with AGT-181 21
Feb 07, 2017: ArmaGen Announces Oral Presentation of Preliminary Results from its Phase 2 Clinical Trial of AGT-181 in Patients with MPS 1 to be Presented at WORLDSymposium 2017 22
Appendix 23
Methodology 23
About GlobalData 23
Contact Us 23
Disclaimer 23

List of Tables
ArmaGen Inc, Pharmaceuticals & Healthcare, Key Facts 2
ArmaGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ArmaGen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ArmaGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ArmaGen Inc, Deals By Therapy Area, 2012 to YTD 2018 8
ArmaGen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
ArmaGen Technologies Raises US$17 Million In Series A Financing 10
ArmaGen Enters into Research Agreement with Rett Syndrome Research Trust 12
Shire Enters into Licensing Agreement with ArmaGen for AGT-182 13
ArmaGen Inc, Key Competitors 14
ArmaGen Inc, Key Employees 15

List of Figures
ArmaGen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ArmaGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ArmaGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ArmaGen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ArmaGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ArmaGen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
ArmaGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ArmaGen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[ArmaGen Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Sumitomo Corp (8053):石油・ガス:M&Aディール及び事業提携情報
    Summary Sumitomo Corp (Sumitomo) is a multifaceted business enterprise. It operates various businesses such as metal products, transportation, construction systems, infrastructure, media, network & lifestyle retail, general products, real estate, financial services, logistics, mineral resources and …
  • CTD Holdings Inc (CTDH):企業の財務・戦略的SWOT分析
    Summary CTD Holdings Inc (CTDH), formerly Cyclodextrin Technologies Development Inc is a biotechnology company that develops, manufactures and distributes cyclodextrins products. The company’s products include aquaplex, trappsol and trappsol cyclo. It provides trappsol cyclo, which is a hydroxypropy …
  • Janssen Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Janssen Pharmaceuticals Inc (Janssen), a subsidiary of Johnson & Johnson is a pharmaceutical company that develops drugs. The company offers medicines for an array of health conditions in therapeutic areas of attention deficit hyperactivity disorder, general medicine, mental health, neurolog …
  • Malaysian Resources Corporation Berhad (MRCB):企業の財務・戦略的SWOT分析
    Malaysian Resources Corporation Berhad (MRCB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stre …
  • Fidelity Investments Inc:企業のM&A・事業提携・投資動向
    Fidelity Investments Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Fidelity Investments Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • CryoPort Inc (CYRX):製薬・医療:M&Aディール及び事業提携情報
    Summary Cryoport, Inc. (Cryoport) is a provider of cold chain logistics solutions for temperature-sensitive biological materials to the life science industries. It offers liquid nitrogen dry vapor shippers with advanced logistics management platform called Cryoportal, which provides credentials rela …
  • Kindred Healthcare, Inc.:戦略・SWOT・企業財務分析
    Kindred Healthcare, Inc. - Strategy, SWOT and Corporate Finance Report Summary Kindred Healthcare, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Hewlett Packard Enterprise Co (HPE):企業の財務・戦略的SWOT分析
    Hewlett Packard Enterprise Co (HPE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Virgin Australia Holdings Limited:企業のM&A・事業提携・投資動向
    Virgin Australia Holdings Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Virgin Australia Holdings Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mer …
  • Excelsior Medical Co Ltd (4104)-医療機器分野:企業M&A・提携分析
    Summary Excelsior Medical Co., Ltd. (Excelsior Medical), formerly Enfield Medical Co., Ltd. is a medical equipment manufacturer that develops and markets products for intraluminal catheter care. The company’s products include SwabCap, SwabFlush, SwabKIT, ZR syringes, flush syringes, PharmAssist and …
  • Altana AG:企業の戦略的SWOT分析
    Altana AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Opthea Ltd (OPT):医療機器:M&Aディール及び事業提携情報
    Summary Opthea Ltd (Opthea), formerly Circadian Technologies Ltd, is a biotechnology company that develops novel biologic therapy for the treatment of eye diseases. The company carries out research and development of angiogenesis and vascular leakage-based treatments for cancer concentrating on vasc …
  • Sumitomo Life Insurance Company:企業のM&A・事業提携・投資動向
    Sumitomo Life Insurance Company - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Sumitomo Life Insurance Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers …
  • The Wendy’s Company:企業の戦略・SWOT・財務情報
    The Wendy’s Company - Strategy, SWOT and Corporate Finance Report Summary The Wendy’s Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Cabot Oil & Gas Corp (COG):石油・ガス:M&Aディール及び事業提携情報
    Summary Cabot Oil & Gas Corp (Cabot) is an independent oil and gas company, which develops, and explores for oil and gas properties primarily in the continental US. It focuses on developing natural gas resources in the Marcellus shale in northeast Pennsylvania and oil development in the Eagle Ford s …
  • Dah Chong Hong Holdings Ltd (1828):企業の財務・戦略的SWOT分析
    Dah Chong Hong Holdings Ltd (1828) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Newpark Resources Inc (NR):企業の財務・戦略的SWOT分析
    Newpark Resources Inc (NR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Dilafor AB:製薬・医療:M&Aディール及び事業提携情報
    Summary Dilafor AB (Dilafor) is a drug development company that develops pharmaceutical products for obstetric indications. The company offers tafoxiparin, a proprietary heparan sulfate mimetic, which is used as an adjuvant therapy to promote cervical ripening and myometrial contractility. Its tafox …
  • Galapagos NV (GLPG):製薬・医療:M&Aディール及び事業提携情報
    Summary Galapagos NV (Galapagos) is a biotechnology company that discovers and develops small molecule medicines. The company’s clinical pipeline include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn’s disease, Phase 2 and 3 trials for ulcerati …
  • J.E. Dunn Construction Group Inc:企業の戦略的SWOT分析
    J.E. Dunn Construction Group Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆